SK Bioscience Secures $3M Grant to Accelerate RSV Antibody Trial
Event summary
- SK Bioscience received a KRW 4 billion ($3 million) grant from the RIGHT Foundation to advance its RSV preventive antibody candidate, RSM01.
- The funding will accelerate the Phase 1b clinical trial of RSM01 in infants.
- RSM01 was licensed from Gates MRI and designed by Adimab, with early studies showing suppression of RSV infection.
- SK Bioscience secured exclusive global supply rights, with non-exclusive rights in India and Gavi-eligible countries.
The big picture
The RSV preventive antibody market is projected to reach $4.5 billion by 2032, driven by expanding immunization coverage in high-income countries and unmet medical needs in lower-income regions. SK Bioscience's strategic focus on both commercial and public health objectives positions it to capitalize on this growing market. The company's integrated development strategy, combining R&D, manufacturing, and supply, aims to secure global competitiveness in the biotech sector.
What we're watching
- Clinical Progress
- The pace at which SK Bioscience advances RSM01 through Phase 1b trials and subsequent stages will determine its competitive positioning in the RSV preventive market.
- Market Strategy
- Whether SK Bioscience can effectively balance commercial value in advanced markets with affordable supply in lower-income countries.
- Pipeline Diversification
- How SK Bioscience's broader infectious disease pipeline, including next-generation vaccines, will contribute to its long-term growth and global competitiveness.
Related topics